Levels of inflammatory markers and the development of the post-thrombotic syndrome

Hadia Shbaklo; Christina A. Holcroft; Susan R. Kahn

doi:10.1160/TH08-08-0511

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 505-512
DOI: 10.1160/TH08-08-0511

Wound Healing and Inflammation/Infection

Schattauer GmbH

Levels of inflammatory markers and the development of the post-thrombotic syndrome

Hadia Shbaklo

¹Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Canada

,

Christina A. Holcroft

¹Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Canada

,

Susan R. Kahn

¹Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Canada

²Division of General Internal Medicine, McGill University, Montreal, Canada

› Author Affiliations

Abstract

Summary

The post-thrombotic syndrome (PTS) occurs frequently after deep venous thrombosis (DVT) despite appropriate anticoagulant therapy. A close relationship between inflammation and thrombosis exists. While the inflammatory process at the time of DVT appears to improve thrombus resolution, it may promote destruction of venous valves, valvular reflux and subsequent development of PTS. We prospectively evaluated the association between levels of four cytokines (IL-6, IL-8, IL-10 and MCP-1), two adhesion molecules (ICAM-1 and VCAM-1) and the development of PTS in a well-defined cohort of patients with DVT. The study population consisted of 387 patients with objectively diagnosed symptomatic DVT who were followed for two years to determine the incidence of PTS. At the end of follow-up, plasma samples frozen at the four-month visit in 307 study patients were thawed and analyzed for the above inflammatory markers using the Luminex beads technology. Mean levels of IL-6 were significantly higher in patients with PTS compared to patients without PTS (7.35 pg/ml ± 14.26 [SD] vs. 4.60 pg/ml ± 4.90;p=0.03). Logistic regression analyses showed significant associations between PTS and levels above vs. below the median of IL-6 [odds ratio (OR) 1.66; 95% confidence interval (CI) 1.05, 2.62 (p=0.03)] and ICAM-1 [OR 1.63; 95% CI 1.03, 2.58 (p=0.04)]. None of the other markers showed any association with PTS. Our study suggests the presence of significant associations between markers of inflammation such as IL-6 and ICAM-1 and the development of PTS. Further work is needed to evaluate this relationship and to analyse other candidate markers that could be implicated etiologically in the association between DVT and PTS. If confirmed, this could lead to identification of new therapeutic targets for preventing PTS after DVT.

Keywords

Post-thrombotic syndrome - deep venous thrombosis - inflammation - interleukins - adhesion molecules

Full Text

References

References
1 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
2 Roumen-Klappe EM, den Heijer M, Janssen MC. et al. The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study. Thromb Haemost 2005; 94: 825-830.
3 Schulman S, Lindmarker P, Holmstrom M. et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4: 734-742.
4 Kahn SR, M‘Lan CE, Lamping DL. et al. The influence of venous thromboembolism on quality of life and severity of chronic venous disease. J Thromb Haemost 2004; 2: 2146-2151.
5 Kahn SR, Elman EA, Bornais C. et al. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. Thromb Haemost 2005; 93: 499-502.
6 Kahn SR, Shbaklo H, Lamping DL. et al. Determinants of health-related quality of life during the two years following deep venous thrombosis. J Thromb Haemost 2008; 6: 1105-1112.
7 Franzeck UK, Schalch I, Jager KA. et al. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich Study). Circulation 1996; 93: 74-79.
8 Markel A, Manzo RA, Bergelin RO. et al. Valvular reflux after deep vein thrombosis: incidence and time of occurrence. J Vasc Surg 1992; 15: 377-382.
9 Prandoni P, Frulla M, Sartor D. et al. Venous abnormalities and the post-thrombotic syndrome. J Thromb Haemost 2005; 3: 401-402.
10 Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.
11 Rao RM, Yang L, Garcia-Cardena G. et al. Endothelial-Dependent Mechanisms of Leukocyte Recruitment to the Vascular Wall. Circ Res 2007; 101: 234-247.
12 Henke PK, Wakefield TW, Kadell AM. et al. Inter-leukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001; 99: 84-91.
13 Humphries J, McGuinness CL, Smith A. et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg 1999; 30: 894-899.
14 Waltham M, Burnand KG, Collins M. et al. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 2000; 32: 988-996.
15 Waltham M, Burnand K, Fenske C. et al. Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. J Vasc Surg 2005; 42: 1183-1189.
16 Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol 2007; 26: 306-311.
17 Ageno W, Dentali F. Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. Thromb Haemost 2008; 100: 181-183.
18 Kahn SR, Ducruet T, Johri M. et al. The economic burden of deep venous thrombosis during the first 4 months following diagnosis: A prospective evaluation. Blood. 2003 11: Abstract 710.
19 Prandoni P, Lensing AWA, Prins MH. et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249-256.
20 Villalta S, Prandoni P, Cogo A. et al. The utility of non-invasive tests for detection of previous proximal-vein thrombosis. Thromb Haemost 1995; 73: 592-596.
21 Kahn SR, Desmarais S, Ducruet T. et al. and VETO Study Investigators. Comparison of performance of two clinical scales to diagnose the post-thrombotic syndrome: Correlation with patient-reported disease burden and valvular reflux. J Thromb Haemost 2006; 4: 907-908.
22 Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362-365.
23 Roumen-Klappe EM, van Rossum J, Janssen MCH. et al. Elevated markers of inflammation in the acute phase of deep-vein thrombosis are a risk factor for elevated venous resistance as a proxy of the post-thrombotic syndrome. J Thromb Haemost. 2007 5: P-W-510.
24 Wakefield TW, Strieter RM, Wilke CA. et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 258-268.
25 Ali T, Humphries J, Burnand K. et al. Monocyte recruitment in venous thrombus resolution. J Vasc Surg 2006; 43: 601-608.
26 Nakai K, Itoh C, Kawazoe K. et al. Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta. Coron Artery Dis 1995; 6: 497-502.
27 Peter K, Nawroth P, Conradt C. et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512.
28 Hackman A, Abe Y, Insull Jr W. et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-1338.
29 Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007; 4: 84-88.
30 Quarmby J, Smith A, Collins M. et al. A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis. J Vasc Surg 1999; 30: 139-147.
31 Smith A, Quarmby JW, Collins M. et al. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost 1999; 82: 1593-1599.
32 Dustin ML, Rothlein R, Bhan AK. et al. Induction by IL 1 and interferon-gamma: tissue distribution, bio-chemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-254.
33 Pigott R, Dillon LP, Hemingway IH. et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-589.
34 Bucek RA, Reiter M, Quehenberger P. et al. The role of soluble cell adhesion molecules in patients with suspected deep vein thrombosis. Blood Coagul Fibrinolysis 2003; 14: 653-657.
35 Smith PC. The causes of skin damage and leg ulceration in chronic venous disease. Int J Low Extrem Wounds 2006; 5: 160-168.
36 Knighton DR, Fiegel VD. The macrophages: effector cell wound repair. Prog Clin Biol Res 1989; 299: 217-226.
37 Knighton DR, Fiegel VD. Macrophage-derived growth factors in wound healing: regulation of growth factor production by the oxygen microenvironment. ARRD 1989; 140: 1108-1111.
38 McGuinness CL, Humphries J, Waltham M. et al. Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost 2001; 85: 1018-1024.
39 Singh I, Burnand KG, Collins M. et al. Failure of thrombus to resolve in urokinase-type plasminogen activator Gene-knockout mice: Rescue by normal bone marrow-derived cells. Circulation 2003; 107: 869-875.
40 Wakefield TW, Linn MJ, Henke PK. et al. Neovascularization during venous thrombosis organization: A preliminary study . J Vasc Surg 1999; 30: 885-893.
41 Phillips LJ, Sarkar R. Molecular characterization of post-thrombotic syndrome. J Vasc Surg 2007; 45 Suppl A A116-A122.
42 Carson RT, Vignali DA. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods 1999; 227: 41-52.
43 de Jager W, te Velthuis H, Prakken BJ. et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-139.
44 Marchena Yglesias PJ, Nieto Rodriguez JA, Serrano MS. et al. Acute-phase reactants and markers of inflammation in venous thromboembolic disease: correlation with clinical and evolution parameters. An Med Interna 2006; 23: 105-110.
45 Kahn SR, Shbaklo H, Shapiro S. et al. Effectiveness of compression stockings to prevent the post-thrombotic syndrome (The SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Dis 2007; 7: 21.
46 Cesari M, Penninx BWJH, Newman AB. et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC Study. Circulation 2003; 108: 2317-2322.
47 Inoue T, Komoda H, Nonaka M. et al. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008; 124: 319-325.
48 Jonsson Y, RubFr M, Matthiesen L. et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Repr Immunol 2006; 70: 83-91.
49 Kilic T, Ural D, Ural E. et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart 2006; 92: 1041-1046.
50 Tzoulaki I, Murray GD, Lee AJ. et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976-983.